Vaccine Protection After Blinatumomab Treatment in Young People With B-Cell Acute Lymphoblastic Leukemia
Checks whether childhood vaccine protection lasts after blinatumomab in young people with B-ALL.
Key facts
- Who runs it
- Arkansas Children's Hospital Research Institute
- Where
- Little Rock and Springdale, United StatesSee the 2 sites
- Trial code
- Registry title
- A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 13 Jan 2026
- Expected to end
- Jan 2029
- Type of study
- Observational, 2 groups
- Record updated
- 28 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with B-cell acute lymphoblastic leukemia or lymphoma. They must have had all the routine vaccines given in the first year of life.
- Age
- From 1 year old up to 21 years old at diagnosis.
- Sex
- All sexes can join.
- Disease stage
- B-lineage acute lymphoblastic leukemia or lymphoma. Relapsed or refractory disease at any time is not allowed.
- Earlier treatment
- Must have had all vaccinations routinely given during the first year of life. Cannot have had, or need, a bone marrow transplant or cellular therapy.
Main reasons for not taking part
- Relapsed or refractory disease at any time
- Received or will need a bone marrow transplant or cellular therapy
- Pregnancy
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Diagnosis of B-lineage acute lymphoblastic leukemia/lymphoma
- ≥1 year old and up to 21 years old at diagnosis
- Informed consent provided, and if applicable, child assent provided
- Must have received all vaccinations routinely administered during first year of life
Who cannot take part
- Received or will require a bone marrow transplant and/or cellular therapy
- Relapsed/refractory disease at any time
- Pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 23 years old?
Where in United States
- Arkansas Children'sLittle Rock, United StatesContact: Stephanie Thomas, RNTaking people
- Arkansas Children's NorthwestSpringdale, United StatesContact: Cristyn Branstetter, MDTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are:
Read full original descriptionShow less
* Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL/Ly who have received blinatumomab. * To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity.
Researchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.
The 2 groups in the trial
- Cases
Participants who have received blinatumomab
- Controls
Participants who have not received blinatumomab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination
- Plain-language title
- Vaccine Protection After Blinatumomab Treatment in Young People With B-Cell Acute Lymphoblastic LeukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07422337, who can take part
- Record updated
- 28 October 2026